Table 3 Adverse events
|  | Febuxostat N = 105 | Benzbromarone N = 109 | Total N = 214 |
|---|---|---|---|
Gout flare | 24 (22.85) | 37 (33.94) | 61 (28.50) |
 Once | 17 (16.19) | 26 (23.85) | 43(20.09) |
 Twice | 5 (4.76) | 11 (10.09) | 16 (7.48) |
 More than twice | 2 (1.90) | 0 | 2(0.93) |
Transaminase elevation from normal | 35(33.33) | 26 (23.85) | 61 (28.50) |
 1~2 × ULN | 25 (23.81) | 22 (20.18) | 47 (21.96) |
 2~3 × ULN | 9 (8.57) | 3 (2.75) | 12 (5.61) |
 > 3 × ULN | 1 (0.95) | 1 (0.92) | 2(0.93) |
New-onset CKD based on CCr | 0 | 4 (3.67) | 4 (1.87) |
 CCr: 50–80 mL min−1 1.73 m−2 | 0 | 4 (3.67) | 4 (1.87) |
 CCr: < 50 mL min−1 1.73 m | 0 | 0 | 0 |
Cardiovascular events | 0 | 0 | 0 |
Skin reaction | 0 | 0 | 0 |
Other adverse events | 0 | 0 | 0 |